

Haematologica
HAEMATOL/2019/236810
Version 3

Selinexor combined with cladribine, cytarabine, and filgrastim in
relapsed or refractory acute myeloid leukemia

Ramzi Abboud, Ezhilarasi Chendamarai, Michael P. Rettig, Kathryn M.
Trinkaus, Peter A. Riedell, Camille N. Abboud, Armin Ghobadi, Iskra
Pusic, Keith Stockerl-Goldstein, Mark A. Schroeder, Ravi Vij, Peter
Westervelt, John F. DiPersio, and Geoffrey L. Uy

Disclosures: Support for this study was provided by Karyopharm Therapeutics. RV has received honoraria from Karyopharm Therapeutics for serving on an advisory board. The authors have no other conflicts relevant to this publication.

Contributions: RA, PAR, and GLU designed and performed research, analyzed data, and wrote the 1st version of the manuscript. EC and MR performed preclinical research and wrote the manuscript. CAN, AG, KSG, IP, MAS, RV, PW, and JFD performed research and edited manuscript. KMT analyzed data.